Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COLD-FX Extra Strength is an over-the-counter botanical supplement developed and marketed by Bausch + Lomb Corporation (formerly Afexa Life Sciences) for immune support and the prevention of cold and flu symptoms. The active ingredient is CVT-E002, a proprietary polysaccharide-rich extract derived from the root of North American ginseng (*Panax quinquefolius*). Each capsule contains 300 mg of CVT-E002, which is a 4:1 extract equivalent to 1,200 mg of dried root. The product is indicated to help reduce the frequency, severity, and duration of cold and flu symptoms by boosting the immune system. Its mechanism of action involves the modulation of immune responses, including effects on cytokine production and the enhancement of innate immune cell activity, although the exact molecular targets are not fully characterized. It is regulated as a Natural Health Product in Canada.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on COLD-FX Extra Strength.